India Preclinical Cro Market Size & Outlook, 2023-2030
India preclinical cro market, 2018-2030 (US$M)
Related Markets
India preclinical cro market highlights
- The India preclinical cro market generated a revenue of USD 183.3 million in 2023 and is expected to reach USD 393.6 million by 2030.
- The India market is expected to grow at a CAGR of 11.5% from 2024 to 2030.
- In terms of segment, toxicology testing was the largest revenue generating service in 2023.
- Bioanalysis and DMPK studies is the most lucrative service segment registering the fastest growth during the forecast period.
Preclinical cro market data book summary
| Market revenue in 2023 | USD 183.3 million |
| Market revenue in 2030 | USD 393.6 million |
| Growth rate | 11.5% (CAGR from 2023 to 2030) |
| Largest segment | Toxicology testing |
| Fastest growing segment | Bioanalysis and DMPK studies |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology |
| Key market players worldwide | Eurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA |
Other key industry trends
- In terms of revenue, India accounted for 3.2% of the global preclinical cro market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China preclinical cro market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 654.3 million by 2030.
Toxicology testing was the largest segment with a revenue share of 22.53% in 2023. Horizon Databook has segmented the India preclinical cro market based on bioanalysis and dmpk studies, toxicology testing, compound management, chemistry, safety pharmacology covering the revenue growth of each sub-segment from 2018 to 2030.
The rising cost of drug research is likely to fuel market growth in the country. Drug makers and sponsors are under pressure to recover revenue lost to generics, increasing patent expiration, number of collaborations to find biologics, and rising R&D costs all of which have increased the cost & complexity of drug development.
Furthermore, the increasing pressure on market participants to adhere to strict schedules raised the demand for research outsourcing. Clinical trials are primarily driven by rising demand for creative solutions in the healthcare business; partnerships between pharma, biotech, & medical devices companies as well as CROs; and technological improvements.
India became one of the most preferred sites for preclinical trials due to developing and cost effective healthcare sector. Also, growing investment from overseas firms for research and development is expected to support market growth over the projected period.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Preclinical CRO Market Scope
Preclinical CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
India preclinical cro market size, by service, 2018-2030 (US$M)
India Preclinical CRO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
